VISCHER advises AC Immune SA in Lausanne in its financing of CHF 20 million ($22.5 million) with existing private investors. The new funds will mainly support the newly initiated groundbreaking clinical trial of the anti-pTau vaccine ACI-35 with patients with mild or moderate Alzheimer’s disease. The VISCHER team is lead by Dr. Matthias Staehelin (Partner) with Christian Wyss (Managing Associate) and Marius Meier (Senior Associate), all Corporate/M&A.